Papers/PMID:21870106
Repeated administration of berberine inhibits cytochromes P450 in humans.
European journal of clinical pharmacology2012The record
2 findings · 1 compound · 2 endpoints
What it reported
How to read these marksWhat moved
2 findings
berberine — inhibits CYP3A4
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“CYP3A4 activity was also inhibited, as the Cmax, AUC0–∞, and AUC0–12 of mid-azolam were increased 38% (P<0.05), 40% (P<0.01), and 37% (P<0.05) after BBR treatment.”
Quoted verbatim from Repeated administration of berberine inhibits cytochromes P450 in humans.. - Study
- crossover
- Duration
- 14 days
- Dose
- berberine 300 mg three times daily orally for 14 days versus placebo; midazolam 2 mg probe
- Population
- Healthy Chinese male volunteers, randomised two-phase crossover with 4-week washout; CYP3A4 activity read from midazolam pharmacokinetics (in vivo probe)
Repeated administration of berberine inhibits cytochromes P450 in humans.2012PMID:21870106Permalink
berberine — inhibits CYP2C9
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“In addition, losartan/E-3174 ratio doubled (P<0.01) after BBR administration, indicating a decrease in CYP2C9 activity.”
Quoted verbatim from Repeated administration of berberine inhibits cytochromes P450 in humans.. - Study
- crossover
- Duration
- 14 days
- Dose
- berberine 300 mg three times daily orally for 14 days versus placebo; losartan 30 mg probe
- Population
- Healthy Chinese male volunteers, randomised two-phase crossover with 4-week washout; CYP2C9 activity read from the 0 to 8 h losartan to E-3174 ratio (in vivo probe)
Repeated administration of berberine inhibits cytochromes P450 in humans.2012PMID:21870106Permalink